Trials / Unknown
UnknownNCT02689037
Angioplasty and Stenting for Patients With Symptomatic Intracranial Atherosclerosis
Angioplasty and Stenting for Patients With Symptomatic Intracranial Atherosclerosis: Study Protocol of a Randomized Controlled Trial
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 394 (estimated)
- Sponsor
- The 476th Hospital of People's Liberation Army · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Background: Effectiveness of Percutaneous transluminal angioplasty and stenting (PTAS) on prevention of events of stroke and death in patients with symptomatic intracranial atherosclerosis (ICAS) is controversial. Aim: to determine whether PTAS plus medical treatment (MT) are superior to MT alone in preventing events of stroke and death in patients with symptomatic ICAS. Methods: The investigators will carry out a randomized controlled trial in 3 hospitals in China. A total of 198 patients with ICAS will be randomized into 2 groups: PTAS+MT and MT group. All patients will receive aspirin (100 mg daily) and clopidogrel (75 mg daily) immediately after randomization, and patients in PTAS+MT group will receive surgery within 5 days after randomization. The patients will be followed up for 1 year after randomization and assessed for events of stroke and death at 30 days and 1 year after randomization, the incidence of recurrent ischaemic stroke in the stenting-involved vascular territory at 30 days and 1 year after randomization, incidence of in-stent restenosis at 1 year after randomization,etc.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Percutaneous transluminal angioplasty and stenting | Surgeons will plant stents after vascular angioplasty in target ICAS vessels within 5 days after randomization. |
| DRUG | Aspirin plus clopidogrel | aspirin 100mg daily and clopidogrel 75mg daily for 90 days |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2018-12-01
- Completion
- 2019-12-01
- First posted
- 2016-02-23
- Last updated
- 2016-04-05
Source: ClinicalTrials.gov record NCT02689037. Inclusion in this directory is not an endorsement.